Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial - PubMed
5 hours ago
- #solid tumors
- #antibody-drug conjugate
- #phase 1/2 trial
- Ifinatamab deruxtecan is a B7-H3-directed antibody-drug conjugate for advanced solid tumors.
- Phase 1/2 trial enrolled 97 patients with treatment-refractory tumors; dose escalation from 0.8-16.0 mg/kg every 3 weeks.
- Maximum tolerated dose was not reached, but one treatment-related death from interstitial lung disease occurred.
- Common grade ≥3 adverse events included anemia (18%), neutropenia (4%), and decreased lymphocyte/neutrophil counts.
- Confirmed objective response rate was 34% across tumor types after median 8.6 months follow-up.
- Promising antitumor activity supports further evaluation in randomized controlled trials.